TrialAntimicrobial agents and chemotherapy2026

Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.

Munjal Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.